MedAware is proud to partner with Ballad Health, to leverage artificial intelligence (AI) to improve patient safety by identifying potential medication-related errors and improving operational efficiency within the pharmacy. Click here to read more.
Dr. John Halamka, MD, MS
John D. Halamka is a Professor of Medicine at Harvard Medical School, President of the Mayo Clinic Platform, Co-chair of the National HIT Standards Committee, Co-chair of the Massachusetts HIT Advisory Committee, and a practicing Emergency Physician. As President of the Mayo Clinic Platform, he is responsible for elevating Mayo Clinic to a global leadership position within digital healthcare, leveraging emerging technologies such as artificial intelligence, connected healthcare devices, and natural language processing. Dr. Halamka has been developing and implementing healthcare information strategies and policies for more than 25 years and specializes in artificial intelligence, the adoption of electronic health records, and the secure sharing of healthcare data for care coordination, population health, and quality improvement. In 2020, Dr. Halamka was elected to the National Academy of Medicine (NAM).
Prof. Isaac Kohane, MD, PhD
Isaac Kohane co-directs the Center for Biomedical Informatics at Harvard Medical School where he applies computational techniques, whole genome analysis, and functional genomics to study human diseases. Kohane has led the use of whole healthcare systems, notably in the i2b2 project, as “living laboratories” to drive discovery research in disease genomics and pharmacovigilance and comparative effectiveness with software and methods adopted in over 84 academic health centers internationally. Dr. Kohane has published over 200 papers and leads a doctoral program in genomics and bioinformatics within the Division of Medical Science at Harvard University.
Dr. Michal Preminger, PhD, MBA
Michal Preminger is Head of Johnson & Johnson Innovation, East North America. Prior to this role, Michal served as the Executive Director of Harvard University’s Office of Technology Development (OTD), where she was responsible for development and commercialization of technologies emerging from research in laboratories and for the strategy and execution of all industry collaborations. Michal holds a PhD in Biological Sciences from the Weizmann Institute of Science, an MBA from INSEAD, Fontainebleau, France, and a BA in Medicine from the Hebrew University of Jerusalem.